‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory)

Improving cardiovascular risk assessment requires a ‘personalized’ approach. Appraisal of well-known cardiovascular risk factors should be integrated with markers of cardiovascular risk such as LDL cholesterol (C-LDL) and C-reactive protein (CRP). Results of the recent trials of PCSK9 inhibitor mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Prati, Francesco, Ruscica, Giovanni, Marco, Valeria, Albertucci, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439940/
https://www.ncbi.nlm.nih.gov/pubmed/30948956
http://dx.doi.org/10.1093/eurheartj/suz029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439940/
https://www.ncbi.nlm.nih.gov/pubmed/30948956
http://dx.doi.org/10.1093/eurheartj/suz029

Ejemplares similares